# Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).

> **NCT06076824** · PHASE4 · UNKNOWN · sponsor: **Hospital General Universitario de Alicante** · enrollment: 100 (estimated)

## Conditions studied

- Heart Block
- Aortic Stenosis
- Bundle-Branch Block

## Interventions

- **DRUG:** Methylprednisolone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06076824
- **Lead sponsor:** Hospital General Universitario de Alicante
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-12
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06076824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06076824, "Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06076824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*